|Prof. Andrey Semechkin Ph.D.||Co-Chairman and Chief Exec. Officer||143.07k||N/A||57|
|Ms. Mahnaz Ebrahimi CPA||Chief Financial Officer and Sec.||187.5k||N/A||60|
|Dr. Russell Kern Ph.D.||Chief Scientific Officer, Exec. VP and Inside Director||196.15k||N/A||31|
|Mr. Kenneth C. Aldrich J.D.||Co-Founder and Chairman Emeritus||N/A||N/A||78|
|Ms. Sophia Garnette||VP of Legal Affairs & Operations||N/A||N/A||N/A|
International Stem Cell Corporation, a clinical stage biotechnology company, focuses on development of therapeutic and biomedical products worldwide. The companys products are based on human parthenogenetic stem cells, a proprietary type of pluripotent stem cells. It develops cell types, including neural stem cells for the treatment of Parkinsons disease and other neurological disorders; liver cells to treat various congenital and acquired liver diseases; islet cells for treatment of diabetes; and retinal cells and three-dimensional eye structures to treat degenerative retinal diseases and corneal blindness, as well as to accelerate corneal healing. The company also develops, manufactures, and markets skincare products and human cell culture products. Its human cell culture products include human skin cells and reagents for the study of skin disease, toxicology, or wound healing; human cells from the heart and blood vessels, and reagents to study cardiovascular disease and cancer; human bronchial and tracheal cell lines for the study of toxicity, cystic fibrosis, asthma, and pathogenesis; and human mammary epithelial cell lines for the study of breast cancer, three dimensional culture, and carcinogen screening. The companys human cell culture products also comprise adult stem cells and reagents for regenerative medicine; human prostate cells and specialized medium to study prostate disease; human renal and bladder cells and media to study renal and bladder diseases; human corneal cells and media for the study of corneal disease; and other cell culture reagents and supplements for the growth, staining, and freezing of human cells. It sells skincare products through a branded Website, professional channels, and distributors; and human cell culture products through its sales force, OEM partners, and brand distributors. International Stem Cell Corporation was founded in 2001 and is headquartered in Carlsbad, California.
International Stem Cell Corporation’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.